Abstracts tagged "cartilage"

Abstract Number: 0557 • ACR Convergence 2020
The Joint Association of Steps/day and Typical Sedentary Bout Length with Worsening Knee Cartilage Damage over Two Years: The MOST Study
Dana Voinier¹, Tuhina Neogi², Joshua Stefanik³, Ali Guermazi², Frank Roemer⁴, Hiral Master⁵, Louise Thoma⁶, Meredith Christiansen⁷, Jason Jakiela¹, Michael Nevitt⁸, Cora Lewis⁹, James Torner¹⁰ and Daniel White¹, ¹University of Delaware, Newark, DE, ²Boston University School of Medicine, Boston, MA, ³Northeastern University, Boston, MA, ⁴Boston University School of Medicine, Boston, MA, and Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany, ⁵Vanderbilt University Medical Center, Nashville, TN, ⁶University of North Carolina at Chapel Hill, Chapel Hill, NC, ⁷University of Delaware, New York, NY, ⁸University of California San Fransisco, Orinda, CA, ⁹University of Alabama Birmingham, Birmingham, AL, ¹⁰University of Iowa, Iowa City, IA
Background/Purpose: Knee cartilage requires loading, e.g., walking, to remain healthy. When cartilage is deprived of loading, i.e., during bouts of sedentary time, it becomes vulnerable…
Abstract Number: PP06 • ACR Convergence 2020
Only in My Dreams Can I Do the Things I Used to Do: Where There Is Research, There Is Hope
Dan Smith¹, Robert Smith¹ and Jillian Covault¹, ¹Canton, MI
Background/Purpose: In Mach 2020, I was diagnosed with relapsing polychondritis ("RP"), a multisystem, rheumatologic disease characterized by inflammation of cartilaginous structures including the ear, nose,…
Abstract Number: 0693 • ACR Convergence 2020
Effect of Physical Activity on Cartilage Degradation and Inflammation in Individuals with Lumbar Spinal Stenosis
Gustavo Almeida¹, Samannaaz Khoja², Lauren Terhorst³, Gwendolyn Sowa⁴, Sara Piva² and Michael Schneider², ¹Department of Physical Therapy, UT HEALTH SAN ANTONIO, San Antonio, TX, ²Department of Physical Therapy, University of Pittsburgh, Pittsburgh, PA, ³Department of Occupational Therapy, University of Pittsburgh, Pittsburgh, PA, ⁴Department of Physical Medicine and Rehabilitation, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Guidelines recommend 150 minutes a week in moderate-intensity physical activity (MPA) to improve health in individuals with chronic disease such as those with lumbar…
Abstract Number: PP10 • ACR Convergence 2020
Patients with Relapsing Polychondritis (“RP”) and an Advocate Manufactured Custom Cloth Masks to Combat COVID-19: This Mask Project Provided a Sense of Purpose, Created Unity, Increased Awareness of RP, Facilitated Research, and Generated Hope
Isabel Bautista¹ and Michael Linn², ¹Relapsing Polychondritis Foundation, Wilmington, CA, ²Relapsing Polychondritis Foundation, New York, NY

Background/Purpose: In 2013, I was diagnosed with Relapsing Polychondritis ("RP"), a systemic inflammatory disease of unknown etiology that can be fatal. The disease affects multiple…
Abstract Number: 28 • 2019 ACR/ARP Annual Meeting
Novel Ex Vivo Model of Septic Arthritis Identifies Role of Neutrophils in Joint Destruction
Kathryn McCall¹, Caroline Atherton ², Neal Millar ², Carl Goodyear ³, Tom Evans ⁴ and Iain McInnes ², ¹Institute of Infection, Immunity & Inflammation, University of Glasgow, Galsgow, United Kingdom, ²Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow, United Kingdom, ³University of Glasgow, Glasgow, United Kingdom, ⁴Institute of Infection, Immunity & Inflammation, University of Glasgow, Glasgow
Background/Purpose: Septic arthritis (SA) caused by bacterial species, such as Staphylococcus aureus, has high morbidity and mortality1. Currently diagnosis is often prolonged and unreliable, with…
Abstract Number: 1001 • 2019 ACR/ARP Annual Meeting
Oral Collagen Type V Supplementation Inhibits Cartilage Degeneration in Experimental Arthritis
Lizandre Keren Silveira ¹, José Eduardo Rodrigues ¹, Silvana Atayde ¹, Sergio Catanozi ¹, Antonio dos Santos Filho ², Vera Luiza Capelozzi ¹, Ricardo Fuller ², Ana Paula Velosa ² and Walcy Teodoro¹, ¹Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil, ²Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR, Sao Paulo, Sao Paulo, Brazil
Background/Purpose: It is known that collagen V (col V) can generate autoimmunity when exposed. In contrast, induction of tolerance with col V supplementation is able…
Abstract Number: 1180 • 2019 ACR/ARP Annual Meeting
Confirmation of Manual Cartilage Segmentation Findings by Automated Segmentation: Retrospective Analysis of MRI Images from a Sprifermin Phase II Study
Alan Brett¹, Michael A Bowes ¹, Philip G Conaghan ², Christoph Ladel ³, Jeffrey Kraines ⁴, Hans Guehring ³, Flavie Moreau ⁴ and Felix Eckstein ⁵, ¹Imorphics, Manchester, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ³Merck KGaA, Darmstadt, Germany, ⁴EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ⁵Paracelsus Medical University, Salzburg, Austria
Background/Purpose: Sprifermin is under investigation as a potential disease-modifying osteoarthritis drug (DMOAD). 2-yr results from the FORWARD study showed significant dose-dependent modification of cartilage thickness…
Abstract Number: 1846 • 2019 ACR/ARP Annual Meeting
Does Cartilage Loss Cause Pain in Osteoarthritis?
KATHRYN BACON¹, Lavalley Michael ² and David Felson ³, ¹Boston University School of Medicine, Boston, MA, ²Boston University, Boston, ³Boston University School of Medicine, Department of Rheumatology, Boston
Background/Purpose: Treatment development in osteoarthritis continues to focus on chondroprotection, but it is unclear if delaying cartilage loss would reduce joint pain. In published studies,…
Abstract Number: 1967 • 2019 ACR/ARP Annual Meeting
Adenosine A2A Receptor Signals Through AMPK and SIRT1 to Increase Chondrocyte Homeostasis
Benjamin Friedman¹ and Bruce Cronstein ², ¹Department of Medicine, Division of Rheumatology NYUSoM, NYC, ²NYU Langone, New York
Background/Purpose: OA is characterized by loss of cartilage and chondrocyte dysfunction. Our lab has shown CGS21680 (CGS, 1µM) activation of adenosine A2AR leads to chondrocyte…
Abstract Number: 1993 • 2019 ACR/ARP Annual Meeting
Inhibition of Choline Kinase Alpha Improves Synovitis and Cartilage Damage in Animal Models of Osteoarthritis
Roxana Coras¹, Leening P Liu ², Serena Z Shi ², Anyan Cheng ³, Alexandra Stubelius ⁴, Elsa Sanchez-Lopez ⁵, Robert Sah ⁶, Ru Liu-Bryan ⁷ and Monica Guma ⁸, ¹Department of Medicine, University of California San Diego, La Jolla, San Diego, CA, ²Department of Bioengineering, University of California San Diego, La Jolla, San Diego, ³Department of Medicine, University of California San Diego, La Jolla, San Diego, ⁴Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, San Diego, ⁵Department of Pharmacology, University of California San Diego, La Jolla, San Diego, ⁶Department of Bioengineering and Medicine, University of California San Diego, La Jolla, San Diego, ⁷San Diego VA/UCSD, La Jolla, CA, ⁸Department of Medicine, School of Medicine. University of California San Diego, La Jolla, United States
Background/Purpose: Osteoarthritis (OA) is a disease of the whole joint, affecting cartilage, ligaments, menisci, bone and synovial tissue. We previously found that choline kinase alpha…
Abstract Number: 2761 • 2019 ACR/ARP Annual Meeting
Cartilage Thickness Modification with Sprifermin in Knee Osteoarthritis Patients Translates into Symptomatic Improvement over Placebo in Patients at Risk of Further Structural and Symptomatic Progression: Post-Hoc Analysis of a Phase II Trial
Hans Guehring¹, Jeffrey Kraines ², Flavie Moreau ², Benjamin Daelken ¹, Christoph Ladel ¹, Wolfgang Wirth ³, Philip G Conaghan ⁴, Felix Eckstein ⁵ and Marc C. Hochberg ⁶, ¹Merck KGaA, Darmstadt, Germany, ²EMD Serono Research and Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³Paracelsus Medical University, Salzbury, Austria, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds & NIHR Leeds Biomedical Research Centre, Leeds, United Kingdom, ⁵Paracelsus Medical University, Salzburg, Austria, ⁶University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Results from the 5-year Phase II FORWARD study showed significant dose-dependent modification of total femorotibial joint (TFTJ) cartilage thickness change with sprifermin at 2…
Abstract Number: 304 • 2018 ACR/ARHP Annual Meeting
Dynamic MRI in Rheumatoid Arthritis for the Assessment of Synovitis Promoting Cartilage Loss
Philipp Sewerin¹, Anja Mueller-Lutz², Matthias Schneider³, Christoph Schleich⁴, Benedikt Ostendorf¹ and Stefan Vordenbäumen⁵, ¹Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine University, Düsseldorf, Germany, ²Department for diagnostic and interventional Radiology, Heinrich-Heine University, Düsseldorf, Germany, ³Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine University, Duesseldorf, Germany, ⁴Department for diagnostic and interventional Radiology, Heinrich-Heine University, Duesseldorf, Germany, ⁵Policlinic for Rheumatology & Hiller Research Centre for Rheumatology, Heinrich-Heine-University Duesseldorf, Düsseldorf, Germany
Background/Purpose: To investigate the local inflammatory activity of the synovium by using dynamic magnetic resonance imaging (MRI) and cartilage biochemical composition of the MCP-joints 2…
Abstract Number: 2006 • 2018 ACR/ARHP Annual Meeting
Murine Ear Wound Cartilage Superhealer Trait Is Associated with Gut Microbiota Changes and Is Transferable to Non-Healer Mice By Gut Microbiome Transplant
Chris Dunn^1,2, Cassandra Velasco^1,3, Madison Andrews^3,4, Alexander Rivas⁵ and Matlock A. Jeffries^2,6, ¹Rheumatology, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ²Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Department of Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁵University of Arkansas for Medical Sciences, Little Rock, AR, ⁶Medicine, University of Oklahoma Health Sciences Center, Oklahoma City, OK
Background/Purpose: MRL/MpJ mice are substantially protected from developing post-traumatic osteoarthritis (OA), a trait with strong correlation to the ability to heal ear wounds. Previous studies…
Abstract Number: 436 • 2018 ACR/ARHP Annual Meeting
Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
Ali Guermazi¹, Jeffrey Kraines², Aida Aydemir², Stephen Wax³, Michel Crema⁴, Marc C. Hochberg⁵ and Frank Roemer^1,6, ¹Radiology, Boston University School of Medicine, Boston, MA, ²EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), Billerica, MA, ³EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany), BIllerica, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵University of Maryland School of Medicine, Baltimore, MD, ⁶Department of Radiology, University of Erlangen-Nuremberg, Erlangen, Germany, Erlangen, Germany
Background/Purpose: Sprifermin, a recombinant human fibroblast growth factor 18, is currently being investigated as a potential disease-modifying OA drug. Sprifermin treatment leads to a dose-dependent…
Abstract Number: 439 • 2018 ACR/ARHP Annual Meeting
Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18)
Ditte Reker¹, Christian S. Thudium², Anne Sofie Siebuhr³, Thorbjørn Gantzel⁴, Christoph Ladel⁵, Martin Michaelis⁵, Morten A. Karsdal², Anne Gigout⁵ and Anne C. Bay-Jensen², ¹Rheumatology, Nordic Bioscience, Biomarkers and Research, Herlev, Denmark, ²Nordic Bioscience, Herlev, Denmark, ³Biomarkers and Research, Nordic Bioscience, Herlev, Denmark, ⁴cOrthopedic Surgery Unit, Gentofte Hospital, Hellerup, Denmark, ⁵Merck KGaA, Darmstadt, Germany
Background/Purpose: Sprifermin, a truncated form of human fibroblast growth factor 18 (FGF18), is being investigated as a potential cartilage and disease-modifying OA drug. In vitro,…

« Previous Page
1
…
3
4
5
6
7
…
15
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].